Menu Back toComparing Accelerated Approval Pathways Among EMA, FDA, and PMDA

DIA 2021 Global Annual Meeting

Comparing Accelerated Approval Pathways Among EMA, FDA, and PMDA

Session Chair(s)

Nobumasa  Nakashima

Nobumasa Nakashima

  • Health Policy Director, National Healthcare Policy Secretariat
  • Cabinet Office, Japan
Early access programs are implemented in EU, Japan, US and many other countries/regions, and many products are approved by utilizing these programs. In this session, speakers share and review the programs and discuss its future direction.
Learning Objective : Outline early access programs provided by each regulatory agency; Discuss the achievements of the early access programs offered by each regulatory agency; Identify how to foster a dialogue among stakeholders on what is expected for the early access programs to further address regulatory needs.


Theresa  Mullin, PhD

FDA Update

Theresa Mullin, PhD

  • Associate Director for Strategic Initiatives, CDER
  • FDA, United States
Agnès  Saint-Raymond, DrMed

EMA Update

Agnès Saint-Raymond, DrMed

  • Head of Division International Affairs
  • European Medicines Agency, Netherlands
Peter  Honig, MD, MPH, FACP

Industry Update

Peter Honig, MD, MPH, FACP

  • Senior Vice President Global Regulatory Affairs and Group Head Development China
  • Pifzer Inc, United States